文献速递腹部技术与安全PETCT

[68Ga]FAPI-04与[18F]FDG PET/CT在胃肠道肿瘤原发灶及转移灶检测中的价值比较

Usefulness of [68Ga]FAPI-04 and [18F]FDG PET/CT for the detection of primary tumour and metastatic lesions in gastrointestinal carcinoma: a comparative study.
PubMed 文献 · Eur Radiol · 2022-11-17

结果显示[68Ga]FAPI-04在检测原发肿瘤、术后复发转移及腹膜转移方面灵敏度显著优于[18F]FDG,且TBR和TLR更高。13例患者根据[68Ga]FAPI-04结果改变了治疗管理。

要点

  • [68Ga]FAPI-04对胃肠道肿瘤原发灶、复发转移及腹膜转移的灵敏度显著高于[18F]FDG。
  • [68Ga]FAPI-04在腹膜转移灶的SUVmax、SUVmean、TBR及TLR均显著高于[18F]FDG。
  • 尽管部分病灶SUVmax相近,FAPI的高TBR/TLR使病灶显示更清晰。

诊断标准与关键数值

  • 患者水平灵敏度:原发肿瘤[68Ga]FAPI-04 94.44%(17/18) vs [18F]FDG 61.11%(11/18),p<0.05。
  • 患者水平灵敏度:术后复发和转移[68Ga]FAPI-04 95.65%(22/23) vs [18F]FDG 69.57%(16/23),p<0.05。
  • 患者水平灵敏度:腹膜转移[68Ga]FAPI-04 100%(28/28) vs [18F]FDG 60.71%(17/28),p<0.05。
  • 腹膜转移灶中位SUVmax:FAPI 12.12 vs FDG 7.18;中位SUVmean:FAPI 6.84 vs FDG 4.11,均p<0.005。
  • 原发灶、淋巴结、肝及腹膜转移灶的TBR和TLR,FAPI均显著高于FDG(均p<0.005)。

临床应用与阅片要点

  • 对于胃肠道肿瘤原发灶及腹膜转移的检出,[68Ga]FAPI-04 PET/CT灵敏度更高,可减少漏诊。
  • FAPI的高TBR和TLR有助于提高病灶对比度,尤其对腹膜转移和小淋巴结的识别。
  • 治疗管理可能因[68Ga]FAPI-04结果而改变(本组13例),提示其在再分期中的潜在价值。

局限性

  • 单中心研究,结果外推需谨慎。
  • 原文未明确研究设计为前瞻性或回顾性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To assess and compare the diagnostic performance of gallium-68-labelled fibroblast activation protein inhibitor ([68Ga]FAPI-04) and fluorine-18 fluorodeoxyglucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) in gastrointestinal cancer.

METHODS: Fifty-one patients who underwent both [18F]FDG and [68Ga]FAPI-04 PET/CT for initial staging or restaging were enrolled. Histopathological findings, typical radiological appearances, and clinical imaging follow-up were used as the reference standard. The diagnostic performance of the two tracers was calculated and compared. The maximum standardised uptake value (SUVmax), mean SUV (SUVmean), tumour-to-mediastinal blood pool ratio (TBR), and tumour-to-liver ratio (TLR) of primary and metastatic lesions were measured and compared between two imaging modalities.

RESULTS: In patient-based analysis, [68Ga]FAPI-04 showed much better diagnostic sensitivity than [18F]FDG in detecting primary tumour (94.44% [17/18] vs. 61.11% [11/18]), postoperative recurrence and metastases (95.65% [22/23] vs. 69.57% [16/23]), and peritoneal carcinomatosis (100% [28/28] vs. 60.71% [17/28]) (all p < 0.05). In lesion-based analysis, [68Ga]FAPI-04 showed higher sensitivity than [18F]FDG for detecting lymph node metastases. In peritoneal carcinomatosis, the median SUVmax (12.12 vs. 7.18) and SUVmean (6.84 vs. 4.11) with [68Ga]FAPI-04 were significantly higher than those with [18F]FDG (all p < 0.005). The TBR and TLR of [68Ga]FAPI-04 were significantly higher than those of [18F]FDG for detecting primary tumour, lymph node, liver, and peritoneal metastases (all p < 0.005). Therapeutic management changed in 13 patients according to [68Ga]FAPI-04 PET/CT compared with conventional imaging.

CONCLUSIONS: [68Ga]FAPI-04 is superior to [18F]FDG PET/CT for detecting primary tumour, postoperative recurrence and metastasis, and peritoneal carcinomatosis in gastrointestinal cancer.

KEY POINTS: • [68Ga]FAPI-04 PET/CT showed significantly higher sensitivity than [18F]FDG PET/CT in the detection of primary tumour and postoperative recurrence and metastasis in patients with gastrointestinal carcinoma. • [68Ga]FAPI-04 PET/CT had obvious advantages over [18F]FDG PET/CT in the detection of peritoneal carcinomatosis from gastrointestinal carcinoma with a much higher FAPI uptake value, TBR, and TLR. • Although the median SUVmax and SUVmean of [68Ga]FAPI-04 were similar to those of [18F]FDG for the primary tumour, lymph node metastases, and liver metastases in gastrointestinal carcinoma, the TBR and TLR of the SUVmax and SUVmean were significantly higher on [68Ga]FAPI-04 PET/CT, causing the lesions to be displayed more clearly.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Li, Tian, Chen, et al. Usefulness of [68Ga]FAPI-04 and [18F]FDG PET/CT for the detection of primary tumour and metastatic lesions in gastrointestinal carcinoma: a comparative study. Eur Radiol. 2022. PMID: 36394603. doi:10.1007/s00330-022-09251-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。